Stock Markets
Protests and politics as Netanyahu addresses US Congress
By Patricia Zengerle
WASHINGTON (Reuters) -Dozens of Democratic lawmakers planned to skip Israeli Prime Minister Benjamin Netanyahu’s speech to Congress on Wednesday, expressing dismay over the thousands of civilian deaths and the humanitarian crisis from Israel’s campaign in Gaza.
The longtime Israeli leader will make a record fourth speech to a joint meeting of the Senate and House of Representatives at 2 p.m. EDT (1800 GMT), passing British wartime leader Winston Churchill, who made three such speeches.
Netanyahu’s speech was expected to focus on coordinating the Israeli and U.S. response to the volatile situation in the Middle East, where there is a growing danger of the Gaza war spilling over into a wider regional conflict.
He was also expected to call for stronger action against Iran, which supports Palestinian Hamas and Lebanese Hezbollah, both militant groups fighting Israel, and has drawn increased U.S. condemnation over its recent nuclear advances.
Republican leaders in Congress orchestrated the visit, but it was likely to be less confrontational than in 2015 when Republicans sidestepped then-President Barack Obama, a Democrat, and Netanyahu used his speech to criticize Obama’s Iran policy.
This time, Netanyahu will seek to bolster his traditional links to Republicans but also look to ease tensions with President Joe Biden, a Democrat whose support he will rely on for the remaining six months of the president’s term.
Washington is preoccupied with the fallout from Biden’s announcement on Sunday that he was ending his reelection bid and endorsing Vice President Kamala Harris for the Democratic presidential nomination to challenge Republican Donald Trump.
SOME LAWMAKERS STAY AWAY
Some lawmakers said they were uncomfortable about appearing to endorse Netanyahu and his hard-right coalition government as he faces declining poll numbers in Israel.
“For him, this is all about shoring up his support back home, which is one of the reasons I don’t want to attend,” Senator Chris Van Hollen told reporters. “I don’t want to be part of a political prop in this act of deception. He is not the great guardian of the U.S.-Israel relationship.”
A Republican House member, Representative Thomas Massie, also said he would not attend. “The purpose of having Netanyahu address Congress is to bolster his political standing in Israel and to quell int’l opposition to his war. I don’t feel like being a prop so I won’t be attending,” he wrote on X.
Some of the most prominent Democrats planned to stay away. They included Senators Dick Durbin, the chamber’s No. 2 Democrat, Tim Kaine, Jeff Merkley and Brian Schatz, all members of the Senate Foreign Relations Committee, as well as Patty Murray, who chairs Senate Appropriations.
In the House, those staying away included progressive Representatives Rashida Tlaib and Alexandria Ocasio-Cortez, as well as Ami Bera, a senior member of the Foreign Affairs Committee, and Adam Smith, the top Democrat on Armed Services.
Smith said he never attends joint meetings but also described himself on Tuesday as “very, very opposed to what Prime Minister Netanyahu is doing in Israel.”
Harris, who normally would preside over the speech as vice president, will not be attending. Neither will Republican Senator JD (NASDAQ:) Vance, Trump’s vice presidential running mate.
Murray would have presided, as the senior Senate Democrat, in Harris’ absence. Democratic Senator Ben Cardin, who leads the foreign relations committee, will replace her.
NETANYAHU TO MEET BIDEN, HARRIS ON THURSDAY
Netanyahu will meet both Biden and Harris on Thursday. Harris has at times been more forward-leaning than her boss in criticizing Israel for heavy Palestinian civilian casualties in Gaza.
Netanyahu was to travel to Florida to meet with Trump on Friday. The meeting will be their first since the end of Trump’s presidency, during which the two forged close ties.
Before addressing Congress, Netanyahu spoke at a memorial for Senator Joe Lieberman, who died in March, stressing the lawmaker’s view that Israel must be allowed to achieve its goal of “disabling Hamas” and that the U.S. and Israel had a shared interest in a united front against Iran.
Several hundred activists staged a demonstration on Tuesday at a congressional office building, and mass protests were promised for Wednesday. The Capitol building was surrounded by high fencing and a heavy security presence.
Some protesters were out on Wednesday hours before Netanyahu’s speech, holding signs including, “Stop War Crimes in Gaza.” Dozens of Washington streets were closed, with some neighborhoods patrolled by New York City police officers.
Some Democrats said they were attending despite their concerns.
“I sit in that chair that I was elected to sit in on days that I enjoy it and days that are iffy and days that I despise it or a mix of the latter two. But I’m elected to be in that seat,” Representative Dan Kildee said.
“My constituents didn’t elect me to show up only when I enjoy what I’m hearing. If I did that I would spend very little time on the floor of the House.”
In a turbulent market environment, Five9 (NASDAQ:) Inc’s stock has touched a 52-week low, reaching a price level of $28.74. This significant downturn reflects a broader trend for the cloud software company, which has seen its shares plummet by -58.79% over the past year. Investors are closely monitoring Five9’s performance as it navigates through a period of heightened volatility and shifting industry dynamics, which have contributed to the stock’s current valuation at this low point. The company’s efforts to rebound from this position will be under scrutiny in the coming quarters as market participants look for signs of a strategic turnaround or further indications of market pressures.
In other recent news, Five9 Inc . has achieved an annual revenue run rate exceeding $1 billion in Q2, a significant milestone despite lowering its annual revenue guidance by 3.8% due to customer budget constraints. The company’s adjusted EBITDA margin rose to 17% of revenue, contributing to a strong operating cash flow of $126 million. The company also confirmed plans to reduce its global workforce by approximately 7% by the end of 2024, a strategic move projected to cost between $12 million and $15 million.
Five9’s recent acquisition of Acqueon, a firm specializing in proactive outbound omnichannel customer engagement, aims to expand its AI offerings and bolster its growth. This move is in line with the company’s focus on managing expenses and improving profitability, with initiatives like FedRAMP and expansion into India anticipated to improve gross margins.
In their analysis, Piper Sandler maintained an Overweight rating for Five9, with a steady price target of $47.00, while Needham and BTIG both maintained a Buy rating with price targets of $48.00 and $45.00 respectively. These ratings reflect the firms’ confidence in Five9’s strategic positioning and potential for growth, despite the current challenges and workforce reduction.
InvestingPro Insights
Amid the current market conditions, Five9 Inc’s recent performance can be put into perspective with select data from InvestingPro. The company’s market capitalization stands at roughly $2.15 billion, indicating the size and scale of the business amidst its challenges. Despite the stock’s decline, analysts are showing a hint of optimism, with 20 analysts having revised their earnings estimates upwards for the upcoming period. This could signal a potential turnaround in sentiment or underlying business performance.
Importantly, Five9’s liquid assets are reported to surpass short-term obligations, suggesting that the company maintains a degree of financial flexibility to navigate its current difficulties. Furthermore, while the stock is trading near its 52-week low, it’s worth noting that the relative strength index (RSI) suggests the stock is in oversold territory, which can sometimes precede a rebound in share price. Investors looking for comprehensive analysis and additional InvestingPro Tips on Five9 can find more insights, including 14 other tips, at https://www.investing.com/pro/FIVN.
In terms of financial health, the company operates with a moderate level of debt and is expected to become profitable this year, according to analysts’ predictions. These elements may offer some solace to investors considering the stock’s substantial price fall over the last year. For those seeking a deeper dive into Five9’s valuation and future prospects, the InvestingPro platform provides a fair value estimate of $45.04, which is considerably higher than the current trading price, suggesting potential undervaluation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TD Cowen reiterated its Buy rating on shares of Terns Pharmaceuticals (NASDAQ:TERN), following the company’s investor call. The call was held to manage expectations for the upcoming Phase 1/2 CARDINAL study data for chronic myeloid leukemia (CML). The firm noted the challenges in measuring the efficacy endpoint (EP) due to disease progression and the absence of treatment switch guidelines, which makes major molecular response (MMR) a challenging efficacy endpoint for Phase 1/2 trials.
The interim Phase 1/2 data aims to evaluate descriptive efficacy signals, considering patients’ baseline BCR-ABL levels and treatment history. The analyst highlighted that the once-daily (QD) dosing and the lack of food effect could potentially enhance the quality of life for patients compared to other allosteric tyrosine kinase inhibitors (TKIs).
Terns Pharmaceuticals has been focusing on the development of improved treatment options for CML. The company’s approach to dosing, which does not require food intake, may offer a more convenient alternative for patients, potentially leading to better adherence and outcomes.
The topline data from the 6-month Phase 1/2 CARDINAL study is anticipated to be available in 2025. This data will provide further insights into the treatment’s efficacy and safety, which are critical factors in the ongoing development and potential approval process.
Investors and stakeholders in Terns Pharmaceuticals are expected to closely monitor the progress of the CARDINAL study, as it could have a significant impact on the company’s future prospects and position in the CML treatment landscape.
In other recent news, Terns Pharmaceuticals has experienced significant developments. The biopharmaceutical company reported robust earnings and revenue results, with Mizuho Securities maintaining an Outperform rating on Terns shares, citing strong enthusiasm for the company’s drug, TERN-701, a potential treatment for chronic myeloid leukemia.
The firm expects the first interim Phase 1 CARDINAL study data for TERN-701 in December.
Terns also announced the appointment of Elona Kogan as its new chief legal officer, a move that underscores the company’s strategic development and pipeline advancement.
The company also secured an extension of its office lease in Foster City, California, through 2027, reflecting Terns Pharmaceuticals’ operational stability and long-term planning.
In terms of clinical trials, Terns has made progress in its ongoing Phase 1 study of TERN-701, with interim findings suggesting the drug can be administered once daily with or without food.
This development, coupled with the forthcoming Phase 1 data for another of Terns’ drugs, TERN-601—an oral GLP-1 receptor agonist for obesity—expected next month, underscores the company’s commitment to innovative therapies.
These recent developments, from financial performance to executive appointments and clinical trials, highlight Terns Pharmaceuticals’ ongoing efforts to advance its strategic objectives and deliver on its mission. The company’s activities are closely watched by investors and industry analysts, including those from Mizuho Securities, who continue to support the company’s potential.
InvestingPro Insights
As Terns Pharmaceuticals (NASDAQ:TERN) navigates the complexities of its Phase 1/2 CARDINAL study, investors are keeping a keen eye on the company’s financial health and stock performance. According to InvestingPro, Terns holds more cash than debt, which is a positive signal for financial stability. Additionally, with five analysts revising their earnings upwards for the upcoming period, there is a sense of optimism about the company’s potential performance.
However, it’s important to note that Terns is not currently profitable and has been quickly burning through cash, which may raise concerns about long-term sustainability. The company’s P/E Ratio stands at -5.71, reflecting these profitability challenges. Despite these hurdles, Terns has managed a 1 Year Price Total Return of 45.42%, indicating some investor confidence in the company’s growth prospects. The anticipated fair value from analysts stands at 15 USD, while the InvestingPro Fair Value is calculated at 5.8 USD, highlighting a divergence in valuation perspectives.
For those looking for more in-depth analysis, additional InvestingPro Tips on Terns Pharmaceuticals can be found at https://www.investing.com/pro/TERN, offering a comprehensive look at the company’s financial details and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PARIS (Reuters) – French President Emmanuel Macron discussed the importance of maintaining support for Ukraine and the need for a ceasefire in Gaza during talks on Friday with German Chancellor Olaf Scholz, said the French presidency.
Regarding Ukraine, the two leaders expressed their determination to support the country “for as long and as intensively as necessary” in its war against Russia, the Elysee said.
Forex2 years agoForex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Forex2 years ago
Unbiased review of Pocket Option broker
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Stock Markets2 years ago
Morgan Stanley: bear market rally to continue
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
